Question: is acalabrutinib approved for cll?
Answer: On November 21, 2019, the Food and Drug Administration approved acalabrutinib (CALQUENCE, AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).